Prothena Presented Phase 1 Study Results Of PRX004 In Oral Presentation At AAN 2021; Said Slowing of Neuropathy Progression for All 7 Evaluable Patients, Evidenced by a +1.29 Point Mean Change in Nis, Was More Favorable Than Expected Progression of +9.2 Points

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!